Is PT-141 or Addyi Better for Low Libido in Women?

Neither PT-141 nor Addyi gives most women a large lift in desire. Both showed only small average gains in trials of low sexual desire that causes distress, which clinicians call hypoactive sexual desire disorder or HSDD. Addyi is a nightly pill with risks of low blood pressure and fainting plus an alcohol rule, while PT-141 sold as Vyleesi is a shot you use only around sex with mainly nausea and flushing and no alcohol interaction.

How much did libido actually improve?

An analysis of the approval trial data found Addyi added about one extra satisfying sexual experience every two months compared with placebo, while bremelanotide added none on that count approval-data analysis.

In two 24-week trials that together included 1,267 women with a mean age of 39, bremelanotide 1.75 mg lowered distress about low desire by 0.33 points more than placebo, a small change with an effect size of 0.27 2020 RECONNECT review. In plain terms, women felt a little less bothered on average, not strongly desirous again.

Those averages come from studies in premenopausal women whose low desire was acquired and generalized. It developed after a period of usual desire and it occurred in most situations. Averages hide wide variation, and the studies did not identify who would respond more.

How do you take them and what feels different?

You take Addyi once daily at bedtime. It carries a boxed warning for low blood pressure and fainting, and the label directs you to avoid alcohol until the next day FDA Addyi label.

You inject Vyleesi under the skin as needed before sex, not daily. Each dose briefly raises blood pressure and lowers heart rate. Readings usually return to usual within 12 hours, so the label directs prescribers to consider heart risk before starting it and during use FDA Vyleesi label.

Day to day effects differ. In trials with 627 women on Vyleesi and 620 on placebo, nausea occurred in 40% compared with 1.3%, flushing in 20.3%, headache in 11.3% and vomiting in 4.8% FDA Vyleesi label. Nausea began a median 30 minutes after the shot and lasted a median 2.4 hours, and the review noted bremelanotide has few to no drug interactions and no adverse interaction with alcohol, unlike flibanserin 2020 RECONNECT review.

Which trade-off might suit you better?

A nightly pill may fit you if you prefer no shots and you can avoid alcohol until the day after each bedtime dose. Addyi labeling now covers women under 65 with acquired generalized HSDD that causes distress and is not due to another condition, relationship strain or a drug effect FDA Addyi label.

An as-needed shot may fit you if you want treatment only around sex and you want no alcohol restriction. Vyleesi labeling covers premenopausal women with the same distressing pattern of acquired generalized HSDD FDA Vyleesi label. The cost of that flexibility is a high chance of short-lived nausea or flushing after each use.

The HOD quiz asks about menopause stage, alcohol use, blood pressure history and dosing preference and sends your answers for clinician review to check fit.